Search research articles
Contact Us
Filters
Showing results (221-230 of 231) with videos related to
Page
of 24
Sort By:
Journal of Medicinal Chemistry
|
September 11, 1998
2-Iminopyrrolidines as potent and selective inhibitors of human inducible nitric oxide synthase
T J Hagen, A A Bergmanis, S W Kramer, et al.
Pain
|
June 11, 2013
Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation
Inmaculada Silos-Santiago, Gerhard Hannig, Helene Eutamene, et al.
ACS Medicinal Chemistry Letters
|
May 19, 2016
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
Takashi Nakai, Nicholas R Perl, Timothy C Barden, et al.
Gastroenterology
|
August 21, 2013
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate
Joel Castro, Andrea M Harrington, Patrick A Hughes, et al.
Frontiers in Pharmacology
|
June 10, 2021
The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases
Susana S Correia, Rajesh R Iyengar, Peter Germano, et al.
Scandinavian Journal of Pain
|
June 19, 2018
Experimental design and reporting standards for improving the internal validity of pre-clinical studies in the field of pain: Consensus of the IMI-Europain consortium
K L Knopp, C Stenfors, C Baastrup, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 13, 2018
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease
Jenny V Tobin, Daniel P Zimmer, Courtney Shea, et al.
Frontiers in Pharmacology
|
April 24, 2020
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease
Daniel P Zimmer, Courtney M Shea, Jenny V Tobin, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
May 22, 2018
Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
N Tofte, M Lindhardt, K Adamova, et al.
JCI Insight
|
February 8, 2022
Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses
Elissa G Currie, Bryan Coburn, Elisa A Porfilio, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 231) with videos related to
Sort By:
Page
of 24
Journal of Medicinal Chemistry
|
September 11, 1998
2-Iminopyrrolidines as potent and selective inhibitors of human inducible nitric oxide synthase
T J Hagen, A A Bergmanis, S W Kramer, et al.
Pain
|
June 11, 2013
Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation
Inmaculada Silos-Santiago, Gerhard Hannig, Helene Eutamene, et al.
ACS Medicinal Chemistry Letters
|
May 19, 2016
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
Takashi Nakai, Nicholas R Perl, Timothy C Barden, et al.
Gastroenterology
|
August 21, 2013
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate
Joel Castro, Andrea M Harrington, Patrick A Hughes, et al.
Frontiers in Pharmacology
|
June 10, 2021
The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases
Susana S Correia, Rajesh R Iyengar, Peter Germano, et al.
Scandinavian Journal of Pain
|
June 19, 2018
Experimental design and reporting standards for improving the internal validity of pre-clinical studies in the field of pain: Consensus of the IMI-Europain consortium
K L Knopp, C Stenfors, C Baastrup, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 13, 2018
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease
Jenny V Tobin, Daniel P Zimmer, Courtney Shea, et al.
Frontiers in Pharmacology
|
April 24, 2020
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease
Daniel P Zimmer, Courtney M Shea, Jenny V Tobin, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
May 22, 2018
Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
N Tofte, M Lindhardt, K Adamova, et al.
JCI Insight
|
February 8, 2022
Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses
Elissa G Currie, Bryan Coburn, Elisa A Porfilio, et al.
Page
of 24